Vaxart (VXRT) Stock Price, News & Analysis

Company Overview

Vaxart, Inc. is a biotechnology company focused on developing oral recombinant vaccines delivered in tablet form. Its proprietary platform is designed to stimulate immune responses at mucosal surfaces, such as those in the nose and mouth, in addition to generating systemic immunity. The company’s approach is intended to offer a needle-free alternative to traditional injectable vaccines.

Vaxart’s development programs have included oral vaccine candidates for coronavirus infections, norovirus and influenza. Its coronavirus research has focused on tablet-based vaccines designed to target respiratory viruses and potentially support protection at the site where infection begins. The company’s candidates remain subject to clinical development and regulatory review, and its products are not broadly marketed vaccines.

Headquartered in South San Francisco, California, Vaxart serves the global biopharmaceutical and vaccine markets through research, development and potential commercialization of oral vaccine products. The company became a publicly traded entity following the 2018 combination of Vaxart and Aviragen Therapeutics, after which the combined company adopted the Vaxart name and continued development of Vaxart’s oral vaccine platform.

Key Stats

• Today's Range: $0.36 to $0.38
• 50-Day Range: $0.36 to $0.50
• 52-Week Range: $0.33 to $0.84
• Volume: 312,466 shs
• Average Volume: 303,788 shs
• Market Capitalization: $90.17 million
• P/E Ratio: 2.85
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Hold

Vaxart Stock Analysis - MarketRank™

Vaxart scored higher than 15% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.0 / 5
• Analyst Rating: Hold

Consensus Rating

Vaxart has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, no buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Vaxart has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Vaxart are expected to decrease in the coming year, from ($0.68) to ($1.03) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Vaxart is 2.85, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 25.14.

Price to Earnings Ratio vs. Sector

The P/E ratio of Vaxart is 2.85, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 34.50.

Price to Book Value per Share Ratio

Vaxart has a P/B Ratio of 1.37. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.02% of the float of Vaxart has been sold short.

Short Interest Ratio / Days to Cover

Vaxart has a short interest ratio ("days to cover") of 3.95, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Vaxart has recently increased by 0.54%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Vaxart does not currently pay a dividend.

Dividend Growth

Vaxart does not have a long track record of dividend growth.

News and Social Media

• Score: 1.6 / 5
• News Sentiment: N/A

News Sentiment

Vaxart has a news sentiment score of -0.49. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.58 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Vaxart this week, compared to 1 article on an average week.

Search Interest

Only 4 people have searched for VXRT on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

MarketBeat Follows

4 people have added Vaxart to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days.

Company Ownership

• Score: 0.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Vaxart insiders have not sold or bought any company stock.

Percentage Held by Insiders

2.80% of the stock of Vaxart is held by insiders.

Percentage Held by Institutions

18.05% of the stock of Vaxart is held by institutions.

Company Calendar

• Last Earnings: 11/05/2026
• Today: 11/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: OTCMKTS:VXRT
• Previous Symbol: NASDAQ:NABI
• CIK: 72444
• Web: www.vaxart.com
• Phone: (650) 550-3500
• Fax: 650-871-8580
• Employees: 65
• Year Founded: 2004

Profitability

• EPS (Trailing Twelve Months): $0.13
• Trailing P/E Ratio: 2.85
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $16.33 million
• Net Margins: 16.02%
• Pretax Margin: 16.42%
• Return on Equity: 35.14%
• Return on Assets: 17.10%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.71
• Quick Ratio: 1.71

Sales & Book Value

• Annual Sales: $237.26 million
• Price / Sales: 0.38
• Cash Flow: $0.10 per share
• Price / Cash Flow: 3.56
• Book Value: $0.27 per share
• Price / Book: 1.37

Miscellaneous

• Outstanding Shares: 243,700,000
• Free Float: 236,878,000
• Market Cap: $90.17 million
• Optionable: No Data
• Beta: 1.15